Rachel E Croft

US Patent:

6783523, Aug 31, 2004

Filed:

Aug 5, 2002

Appl. No.:

10/212311

Inventors:

Jay Qin - Fremont CA
Robin Bek - Campbell CA
John Gaiser - Mountain View CA
Rachel Croft - San Francisco CA
Peter Muller - Los Gatos CA
David S Utley - Redwood City CA

Assignee:

Curon Medical, Inc. - Fremont CA

International Classification:

A61B 1900

US Classification:

606 1, 606 41

Abstract:

Unified systems and methods enable control of the use and operation of a family of different treatment devices, to treat dysfunction in different regions of the body.

US Patent:

6790207, Sep 14, 2004

Filed:

Nov 26, 2001

Appl. No.:

09/994375

Inventors:

David S. Utley - San Carlos CA
John W Gaiser - Mountain View CA
Rachel Croft - San Francisco CA

Assignee:

Curon Medical, Inc. - Fremont CA

International Classification:

A61B 1818

US Classification:

606 41, 128898, 607133

Abstract:

Systems and methods that treat disorders of the gastrointestinal tract by applying one or more treatment agents to tissue at or near the region where abnormal neurological symptoms or abnormal tissue conditions exist. The treatment agent is selected to either disrupt the abnormal nerve pathways and/or to alleviate the abnormal tissue conditions. The treatment agent can include at least one cytokine and/or at least one vanilloid compound to evoke a desired tissue response. The systems and methods can be used a primary treatment modality, or as a neoadjuvent or adjuvant treatment modality.

US Patent:

6802841, Oct 12, 2004

Filed:

Nov 26, 2001

Appl. No.:

09/994379

Inventors:

David S Utley - San Carlos CA
John W Gaiser - Mountain View CA
Rachel Croft - San Francisco CA

Assignee:

Curon Medical, Inc. - Fremont CA

International Classification:

A61B 1818

US Classification:

606 41, 128898, 607133

Abstract:

Systems and methods apply a selected treatment agent or agents into contact with tissue at or in the region of a dysfunctional sphincter (in the case of GERD, fecal incontinence, or other dysfunctional sphincter disorders) to affect improved sphincter barrier function and/or to disrupt abnormal nerve pathways. The treatment agent can include at least one cytokine and/or at least one tissue bulking agent and/or at least one vanilloid compound to evoke a desired tissue response. The systems and methods can be used a primary treatment modality, or applied as a supplementary treatment before, during or after a primary intervention.

US Patent:

7056320, Jun 6, 2006

Filed:

Sep 29, 2003

Appl. No.:

10/674242

Inventors:

David Utley - San Carlos CA, US
Scott West - Livermore CA, US
John Gaiser - Mountain View CA, US
Rachel Croft - San Francisco CA, US

Assignee:

Curon Medical, Inc. - Fremont CA

International Classification:

A61B 18/18

US Classification:

606 41, 128898

Abstract:

A sphincter tissue region is treated using a support structure sized for advancement into the anal canal. At least one electrode is carried by the structure. A mechanism is coupled to the electrode to move the electrode between a first position retracted in the support structure and a second position extended from the support structure through surface tissue to penetrate a subsurface tissue region at or near a sphincter in the anal canal. A cable is coupled to the electrode to conduct energy for application by the electrode to form a lesion in the subsurface tissue region.

US Patent:

7160294, Jan 9, 2007

Filed:

Sep 2, 2003

Appl. No.:

10/653448

Inventors:

Rachel Croft - San Francisco CA, US

Assignee:

Curon Medical, Inc. - Fremont CA

International Classification:

A61B 18/18

US Classification:

606 41, 607101, 607133

Abstract:

Systems and methods treat hemorrhoids by introducing a treatment device into the anal canal to extend above a hemorrhoidal plexus and adjacent a tissue region containing blood vessels that feed the hemorrhoidal plexus. The systems and methods operate the treatment device to affect tissue morphology in the tissue region to occlude or otherwise reduce blood flow through the vessels.

US Patent:

7293563, Nov 13, 2007

Filed:

Aug 5, 2004

Appl. No.:

10/912268

Inventors:

David Utley - San Carlos CA, US
John W Gaiser - Mountain View CA, US
Rachel Croft - San Francisco CA, US

Assignee:

Curon Medical, Inc. - Fremont CA

International Classification:

A61B 19/00

US Classification:

128898, 606 41, 607133

Abstract:

Systems and methods that treat disorders of the gastrointestinal tract by applying one or more treatment agents to tissue at or near the region where abnormal neurological symptoms or abnormal tissue conditions exist. The treatment agent is selected to either disrupt the abnormal nerve pathways and/or to alleviate the abnormal tissue conditions. The treatment agent can include at least one cytokine and/or at least one vanilloid compound to evoke a desired tissue response. The systems and methods can be used a primary treatment modality, or as a neoadjuvent or adjuvant treatment modality.

US Patent:

7458378, Dec 2, 2008

Filed:

Aug 5, 2004

Appl. No.:

10/912329

Inventors:

David S Utley - San Carlos CA, US
John W Gaiser - Mountain View CA, US
Rachel Croft - San Francisco CA, US

Assignee:

Respiratory Diagnostics, Inc. - Redmond WA

International Classification:

A61B 19/00
A61B 18/18

US Classification:

128898, 606 41, 607133

Abstract:

Systems and methods apply a selected treatment agent or agents into contact with tissue at or in the region of a dysfunctional sphincter (in the case of GERD, fecal incontinence, or other dysfunctional sphincter disorders) to affect improved sphincter barrier function and/or to disrupt abnormal nerve pathways. The treatment agent can include at least one cytokine and/or at least one tissue bulking agent and/or at least one vanilloid compound to evoke a desired tissue response. The systems and methods can be used a primary treatment modality, or applied as a supplementary treatment before, during or after a primary intervention.

US Patent:

7468060, Dec 23, 2008

Filed:

Nov 8, 2002

Appl. No.:

10/291862

Inventors:

David S. Utley - Redwood City CA, US
Rachel E. Croft - San Francisco CA, US
John Gaiser - Mountain View CA, US

Assignee:

Respiratory Diagnostic, Inc. - Redmond WA

International Classification:

A61B 18/18
A61N 1/00

US Classification:

606 41, 607133, 128898

Abstract:

Systems and methods affect tightening of the pyloric sphincter and/or serve to mediate or moderate receptive relaxation of muscles in the stomach, to treat or mitigate various physiologic conditions, such as obesity, biliary reflex, GERD, and/or Barrett's esophagus. The systems and methods may be used as either a primary treatment modality, or applied as a supplementary treatment before, during or after a primary intervention.